How many therapies never reach patients because capital flows to the best story instead?
Every founder knows the grind: months of experiments, a flawless grant package, and then the rejection that says “not relevant.” Meanwhile, headlines celebrate another startup raising millions for an AI-powered wellness gadget. Funding Nightmares captures that moment, when real science collides with a system built to reward the story, not the data.
So the question is simple: who needs a cure when you can track your aura?
Other Scienz & Lives comics
Failing Like A Champ
“Fail fast” was meant to drive smarter decisions. Instead, it became a slogan that excuses repetition. In biotech, failure teaches only when it’s deliberate. Everything else is just theater.
From Billions to Bills
Biotech headlines show billion-euro deals, but real success often means surviving another quarter. In this Scienz & Lives story, optimism meets the invoice.
Science Meets Happy Hour
Science fills the program, but networking shapes the outcome. In this Scienz & Lives story, the spotlight shifts from the podium to the people behind the progress.
Funding Nightmares: Science or Vibes?
How many therapies never reach patients because capital flows to the best story instead?
Results Before Rules
What’s the worst that could happen if you skip ethics approval? Let’s say someone’s about to learn what “violation report” means.
Fake it till they fund it
When your fake deck gets more investor interest than your real science, you start to wonder which one the industry actually values.
AI Discovery Engine
In today’s sketch, Scienz unveils their fully AI-driven pipeline. Lives asks the obvious question: what does the AI actually do? And the answer is both impressive and deeply concerning.
Endless Pitch
Decks get edited. Again. And again. Until the science is vague, the font is sacred, and no one remembers what the original idea was. That’s the grind behind fundraising in biotech. You are selling potential, not results. But the pressure to sound like a sure thing...
The VC Paradox: Sell the Dream, Not the Details
Startups often lose their shine the moment they start showing their work. In venture capital, mystery creates momentum. This article explores why over-explaining too soon can backfire, and how founders can strike a better balance between transparency and vision when raising money.
Scientific Objectivity: The Story We Tell Ourselves
Scientific objectivity is the gold standard but in practice, it’s often an elegant illusion. From selective data inclusion to subtle narrative choices, even the most well-meaning scientists shape the story. This piece explores the quiet biases behind the scenes, why interpretation is never neutral, and how honesty (and a little humor) can actually make science stronger.